CN104011203A - 视网膜变性疾病的治疗方法 - Google Patents

视网膜变性疾病的治疗方法 Download PDF

Info

Publication number
CN104011203A
CN104011203A CN201280049453.2A CN201280049453A CN104011203A CN 104011203 A CN104011203 A CN 104011203A CN 201280049453 A CN201280049453 A CN 201280049453A CN 104011203 A CN104011203 A CN 104011203A
Authority
CN
China
Prior art keywords
cells
retinal
wnt
cell
signaling pathway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280049453.2A
Other languages
English (en)
Chinese (zh)
Inventor
玛丽亚·皮娅·卡斯马
丹妮拉·桑格斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN104011203A publication Critical patent/CN104011203A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201280049453.2A 2011-08-05 2012-08-06 视网膜变性疾病的治疗方法 Pending CN104011203A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11176713.3 2011-08-05
EP11176713A EP2554662A1 (en) 2011-08-05 2011-08-05 Methods of treatment of retinal degeneration diseases
PCT/EP2012/065327 WO2013020945A1 (en) 2011-08-05 2012-08-06 Methods of treatment of retinal degeneration diseases

Publications (1)

Publication Number Publication Date
CN104011203A true CN104011203A (zh) 2014-08-27

Family

ID=46826437

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280049453.2A Pending CN104011203A (zh) 2011-08-05 2012-08-06 视网膜变性疾病的治疗方法

Country Status (15)

Country Link
US (1) US20140199277A1 (cg-RX-API-DMAC7.html)
EP (2) EP2554662A1 (cg-RX-API-DMAC7.html)
JP (1) JP2014527407A (cg-RX-API-DMAC7.html)
KR (1) KR20140068936A (cg-RX-API-DMAC7.html)
CN (1) CN104011203A (cg-RX-API-DMAC7.html)
AR (1) AR087471A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012293681A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014002718A8 (cg-RX-API-DMAC7.html)
CA (1) CA2844106A1 (cg-RX-API-DMAC7.html)
CO (1) CO7081142A2 (cg-RX-API-DMAC7.html)
IL (1) IL230830A0 (cg-RX-API-DMAC7.html)
MX (1) MX2014001475A (cg-RX-API-DMAC7.html)
RU (1) RU2014108478A (cg-RX-API-DMAC7.html)
SG (1) SG2014008080A (cg-RX-API-DMAC7.html)
WO (1) WO2013020945A1 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108603167A (zh) * 2015-09-15 2018-09-28 思特科技公司 使用其中引入nanog的源自羊水胎儿的间充质干细胞制备用于促进毛发生长的组合物的方法
CN109414416A (zh) * 2016-07-07 2019-03-01 国民大学校产学协力团 倍半萜衍生物的新用途
CN110267972A (zh) * 2016-11-06 2019-09-20 纳秒示波器科技有限公司 由多特征视蛋白进行的用于视力恢复的光学调制以及其其他应用
CN110706164A (zh) * 2019-09-03 2020-01-17 北京爱博同心医学科技有限公司 基于增强现实的管状视野图像变形显示方法及眼镜

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013045694A1 (en) 2011-09-29 2013-04-04 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Compositions and methods for the treatment of degenerative retinal conditions
SG11201605833PA (en) 2014-01-17 2016-08-30 Sumitomo Chemical Co Method for manufacturing ciliary margin stem cells
IL251178B (en) * 2014-09-16 2022-07-01 Genzyme Corp Adeno-associated viral vector for the treatment of glaucoma myocilin (myoc)
RU2569481C1 (ru) * 2014-12-25 2015-11-27 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ получения культуры клеток ретинального пигментного эпителия из глаза взрослого донора-трупа
RU2578526C1 (ru) * 2014-12-25 2016-03-27 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ получения органной культуры хороидально-пигментного комплекса из глаза взрослого донора-трупа
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
EP3484463B1 (en) * 2016-08-19 2020-02-12 The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology Transfer Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
JP2020518915A (ja) 2017-04-27 2020-06-25 パスハラキス スタブロスPASCHALAKIS, Stavros 自動眼底画像分析用のシステムおよび方法
AR111808A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
PE20191787A1 (es) 2017-05-18 2019-12-24 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituidos
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
KR102612140B1 (ko) 2017-05-18 2023-12-08 이도르시아 파마슈티컬스 리미티드 피리미딘 유도체
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
JP7376092B2 (ja) * 2017-06-15 2023-11-08 ザ ユニバーシティ オブ ノース テキサス ヘルス サイエンス センター アット フォート ワース 網膜細胞への線維芽細胞の再プログラミング方法
CN117159463A (zh) * 2017-08-20 2023-12-05 加州大学董事会 治疗青光眼的Wnt5a的调节
US20220040236A1 (en) * 2018-04-06 2022-02-10 Icahn School Of Medicine At Mount Sinai Compositions and methods of treatment of vision loss through generation of rod photoreceptors from müller glial cells
EP3937955A4 (en) * 2019-03-15 2022-12-07 The Schepens Eye Research Institute, Inc. ISOLATION, ENHANCEMENT AND EXPANSION OF CONICAL PROGENITOR CELLS AND THEIR USES
US12558336B2 (en) 2019-09-25 2026-02-24 The Board Of Trustees Of The Leland Stanford Junior University Metabolic rescue of retinal degeneration
KR20210119766A (ko) * 2020-03-25 2021-10-06 서울대학교병원 인간 배아줄기세포 유래 중간엽 줄기세포를 포함하는 망막색소변성의 예방 또는 치료용 약학적 조성물
KR102655748B1 (ko) * 2023-06-08 2024-04-05 충북대학교 산학협력단 고포도당 조건에서의 중간엽 줄기세포의 생존율을 증가시키는 방법
KR102655735B1 (ko) * 2023-06-09 2024-04-05 충북대학교 산학협력단 당뇨성 망막병증의 예방 및 치료를 위한 타크로리무스 전처리 줄기세포
TW202604507A (zh) 2024-05-02 2026-02-01 瑞士商愛杜西亞製藥有限公司 經n-取代之吲哚衍生物的結晶形式

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050129665A1 (en) * 2002-07-25 2005-06-16 Martin Friedlander Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
CN1816281A (zh) * 2003-05-02 2006-08-09 斯克里普斯研究学院 造血干细胞及其治疗新生血管性眼疾的方法
EP2090649A1 (en) * 2008-02-13 2009-08-19 Fondazione Telethon Method for reprogramming differentiated cells
WO2010029288A2 (en) * 2008-09-11 2010-03-18 Axordia Limited Growth factor
CN101835891A (zh) * 2007-06-15 2010-09-15 加内特生物治疗学股份有限公司 运用体外培养增殖的自我更新型集落形成细胞治疗疾病和功能紊乱症
WO2011043591A2 (en) * 2009-10-06 2011-04-14 Snu R&Db Foundation Method for differentiation into retinal cells from stem cells

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6128654A (en) 1997-02-14 2000-10-03 Advanced Micro Devices, Inc. Method and apparatus for transmitting multiple copies by replicating data identifiers
DE69919707T2 (de) 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
CN1272328C (zh) 1999-12-17 2006-08-30 希龙公司 糖元合成酶激酶3的基于吡嗪的抑制剂
ES2246927T3 (es) 1999-12-17 2006-03-01 Chiron Corporation Inhibidores biciclicos de glucogeno sintasa quinasa 3.
WO2002020495A2 (en) 2000-09-06 2002-03-14 Chiron Corporation Inhibitors of glycogen synthase kinase 3
BRPI0113757B8 (pt) 2000-09-11 2017-11-07 Chiron Corp derivados de quinolinona como inibidores de tirosina quinase
WO2002096905A1 (en) 2001-06-01 2002-12-05 Vertex Pharmaceuticals Incorporated Thiazole compounds useful as inhibitors of protein kinases
KR20040084896A (ko) 2002-02-06 2004-10-06 버텍스 파마슈티칼스 인코포레이티드 Gsk-3의 억제제로서 유용한 헤테로아릴 화합물
EP1490093A4 (en) 2002-03-01 2007-04-11 Novartis Vaccines & Diagnostic METHOD AND COMPOSITIONS FOR TREATING ISCHEMIA
US7838290B2 (en) * 2002-07-25 2010-11-23 The Scripps Research Institute Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
CA2496246A1 (en) 2002-08-23 2004-03-04 Chiron Corporation Pyrrole based inhibitors of glycogen synthase kinase 3
CN1717391A (zh) 2002-10-21 2006-01-04 希龙公司 糖元合成酶激酶3的抑制剂
JP2007502300A (ja) 2003-08-13 2007-02-08 カイロン コーポレイション Gsk−3インヒビターおよびその使用
EP1802199A4 (en) * 2004-09-03 2008-08-27 Scripps Research Inst HEMATOPOIETIC STEM CELLS OF ISOLATED NEGATIVE LINES AND METHODS OF TREATMENT THEREOF
US7850960B2 (en) * 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
US20070231306A1 (en) * 2005-02-24 2007-10-04 The Scripps Research Institute Isolated myeloid-like cell populations and methods of treatment therewith
RU2403906C2 (ru) 2005-02-24 2010-11-20 Дзе Скриппс Рисерч Инститьют Способ лечения ретинопатии при недоношенности и родственных ретинопатических заболеваний
JP2009500297A (ja) * 2005-06-08 2009-01-08 セントカー・インコーポレーテツド 眼の変性についての細胞療法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050129665A1 (en) * 2002-07-25 2005-06-16 Martin Friedlander Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
CN1816281A (zh) * 2003-05-02 2006-08-09 斯克里普斯研究学院 造血干细胞及其治疗新生血管性眼疾的方法
CN101835891A (zh) * 2007-06-15 2010-09-15 加内特生物治疗学股份有限公司 运用体外培养增殖的自我更新型集落形成细胞治疗疾病和功能紊乱症
EP2090649A1 (en) * 2008-02-13 2009-08-19 Fondazione Telethon Method for reprogramming differentiated cells
WO2010029288A2 (en) * 2008-09-11 2010-03-18 Axordia Limited Growth factor
WO2011043591A2 (en) * 2009-10-06 2011-04-14 Snu R&Db Foundation Method for differentiation into retinal cells from stem cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HITOMI AOKI ET AL.: "Embryonic stem cells that differentiate into RPE cell precursors in vitro develop into RPE cell monolayers in vivo", 《EXPERIMENTAL EYE RESEARCH》 *
JIN-A KIM ET AL.: "Identification of a Stroma-Mediated Wnt/b-Catenin Signal Promoting Self-Renewal of Hematopoietic Stem Cells in the Stem Cell Niche", 《STEM CELLS》 *
TOSHIHIRO INOUE ET AL.: "Activation of Canonical Wnt Pathway Promotes Proliferation of Retinal Stem Cells Derived from Adult Mouse Ciliary Margin", 《STEM CELLS》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108603167A (zh) * 2015-09-15 2018-09-28 思特科技公司 使用其中引入nanog的源自羊水胎儿的间充质干细胞制备用于促进毛发生长的组合物的方法
CN108603167B (zh) * 2015-09-15 2022-01-21 思特科技公司 使用nanog引入的源自羊水胎儿的间充质干细胞制备用于促进毛发生长的组合物的方法
CN109414416A (zh) * 2016-07-07 2019-03-01 国民大学校产学协力团 倍半萜衍生物的新用途
CN109414416B (zh) * 2016-07-07 2021-03-26 国民大学校产学协力团 倍半萜衍生物的新用途
CN110267972A (zh) * 2016-11-06 2019-09-20 纳秒示波器科技有限公司 由多特征视蛋白进行的用于视力恢复的光学调制以及其其他应用
CN110706164A (zh) * 2019-09-03 2020-01-17 北京爱博同心医学科技有限公司 基于增强现实的管状视野图像变形显示方法及眼镜

Also Published As

Publication number Publication date
RU2014108478A (ru) 2015-09-10
MX2014001475A (es) 2014-07-22
EP2739723A1 (en) 2014-06-11
IL230830A0 (en) 2014-03-31
AR087471A1 (es) 2014-03-26
CA2844106A1 (en) 2013-02-14
WO2013020945A9 (en) 2013-04-04
WO2013020945A1 (en) 2013-02-14
US20140199277A1 (en) 2014-07-17
EP2554662A1 (en) 2013-02-06
JP2014527407A (ja) 2014-10-16
SG2014008080A (en) 2014-03-28
NZ621345A (en) 2015-09-25
CO7081142A2 (es) 2014-10-10
BR112014002718A2 (pt) 2017-06-13
AU2012293681A1 (en) 2014-03-06
KR20140068936A (ko) 2014-06-09
BR112014002718A8 (pt) 2017-06-20

Similar Documents

Publication Publication Date Title
US20140199277A1 (en) Methods of Treatment of Retinal Degeneration Diseases
US10787641B2 (en) Therapeutic use of CD31 expressing cells
TWI921638B (zh) 包含經由血管母細胞產生之間葉基質細胞之醫藥組合物
CN101484575B (zh) 用于眼变性的细胞疗法
Kemp et al. Fusion between human mesenchymal stem cells and rodent cerebellar Purkinje cells
Huang et al. Class II transactivator knockdown limits major histocompatibility complex II expression, diminishes immune rejection, and improves survival of allogeneic bone marrow stem cells in the infarcted heart
JP2025028314A (ja) 網膜系細胞又は網膜組織の障害を伴う疾患の治療薬
JP2017113037A (ja) 胞子様細胞の亜集団およびその用途
US20260109949A1 (en) T cell production method
KR20170093178A (ko) 전구 세포를 사용한 안구 질환의 치료
Mussar et al. Macrophage/epithelium cross-talk regulates cell cycle progression and migration in pancreatic progenitors
KR20120060201A (ko) 기능적으로 분화된 체세포의 연장된 자기재생을 유도하는 방법
US20200347352A1 (en) Methods and system of human hemogenic reprograming
CA2628530C (en) Novel stem cells, nucleotide sequences and proteins therefrom
WO2015125941A1 (ja) 眼疾患治療剤、そのスクリーニング方法または網膜色素上皮細胞移植に伴う拒絶反応の予測方法
JP2023513632A (ja) 血小板由来ミトコンドリア治療及び多能性細胞の生成方法
KR20180088713A (ko) 전구 세포를 사용한 망막 변성의 치료
NZ621345B2 (en) Methods of treatment of retinal degeneration diseases
ALSHARIF Thymic recovery following chemotherapy damage–the impact of sex hormones and ageing
WO2022009969A1 (ja) 網膜色素上皮細胞の移植用生着促進剤
Erika The immunomodulatory and pro-regenerative capacity of mesenchymal stromal cells and their therapeutic use for kidney disease
Tysoe The Immunogenicity of Cholangiocyte Cellular Therapies
Morad Mesenchymal stem cells: Differentiation, hematopoietic support and possible application in cell and gene therapy for osteoarthritis
Tan et al. Hematopoietic stem cells and somatic stem cells
Mathews Ex vivo expansion and induced transdifferentiation of rabbit bone marrow messenchymal stem cells to corneal lineage by simulating corneal stem cell niche

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140827

WD01 Invention patent application deemed withdrawn after publication